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Neurodegenerative diseases present a current challenge for accurate diagnosis and for providing precise prognostic information.
Developing imaging biomarkers for multiple sclerosis (MS), Parkinson disease (PD), and Alzheimer’s disease (AD) will improve
the clinical management of these patients and may be useful for monitoring treatment effectiveness. Recent research using optical
coherence tomography (OCT) has demonstrated that parameters provided by this technology may be used as potential biomarkers
for MS, PD, and AD. Retinal thinning has been observed in these patients and new segmentation software for the analysis of
the different retinal layers may provide accurate information on disease progression and prognosis. In this review we analyze the
application of retinal evaluation using OCT technology to provide better understanding of the possible role of the retinal layers
thickness as biomarker for the detection of these neurodegenerative pathologies. Current OCT analysis of the retinal nerve fiber
layer and, specially, the ganglion cell layer thickness may be considered as a good biomarker for disease diagnosis, severity, and
progression.
1. Introduction
Neurodegenerative disorders present a current challenge
for accurate diagnosis and for providing precise prognostic
information. Some diseases, such as multiple sclerosis (MS),
present with an unpredictable course, whereas others, such
as Parkinson disease (PD) and Alzheimer’s disease (AD),
may take several years to obtain a definitive diagnosis.
Due to increased aging population in developed countries,
neurodegenerative diseases such as PD and AD have become
more prevalent and thus new technologies andmore accurate
tests are needed to improve and accelerate the diagnostic
procedure in early stages of these diseases.
Developing imaging biomarkers for MS, PD, and AD
in order to provide early diagnosis and predict the clinical
course and future disability will improve the clinical man-
agement of these patients and may be useful for monitoring
treatment effectiveness as well.
Optical coherence tomography (OCT) provides cross-
sectional imaging of internal structures in biological tissues
[1, 2]. Recent research using OCT technology has demon-
strated that parameters provided by OCT are accurate to
detect various inner retinal or optic nerve pathologies. In the
last decade this technique has also been applied in several
areas in neurology, demonstrating its potential role as a
fundamental tool in the study of neurodegenerative diseases,
such as MS, PD, or AD [3–9]. At the present time, however,
no clear guidelines are available on whether one, several, or
all of the retinal parameters measured by OCT can be used
in the diagnosis of these pathologies, and therefore the use of
OCT technology in the clinical management of neurological
patients is limited to follow disease progression in several
common pathologies.
In the present article, we review the application of retinal
evaluation using OCT technology to provide better under-
standing of the possible role of the retinal layers thickness as
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biomarker for the detection of neurodegenerative pathologies
such as MS, PD, and AD.
2. Multiple Sclerosis
Multiple sclerosis (MS) is a neurodegenerative disease char-
acterized by demyelination and axonal degeneration in the
central nervous system, leading to progressive neurologic
deficits [10, 11]. Axonal damage already occurs in the early
stages of the disease, not being related to inflammatory or
autoimmune episodes against myelin [12, 13].
The retina of patients with MS displays inflammatory
and neurodegenerative findings, such as perivascular inflam-
matory infiltrates and atrophy of the inner retinal layers
[14]. In 1999, Parisi et al. reported for the first time a
significant reduction in the retinal nerve fiber layer (RNFL)
of patients with MS and previous optic neuritis (MSON)
compared to healthy subjects and its correlation with pattern
electroretinogram changes in these eyes [15]. Since then, an
increased interest in the application of OCT technology led
to a large number of studies on the retinal changes in MS
patients with and without previous ON episodes (non-ON).
So far, studies using spectral-domain OCT have revealed that
the retina in non-ON eyes shows thinner peripapillary RNFL
(pRNFL) than healthy controls [16–19].
2.1. RNFL Thickness as a Biomarker of Disease Severity and
Progression in MS. The introduction in the last few decades
of OCT in the study of MS has provided new information
on correlations between visual deficiencies and retinal alter-
ations in these patients and also between pRNFL thinning
and disability [9]. Recent studies using OCT showed that low
contrast letter acuity scores in MS patients reflect the axonal
and neuronal losses in the anterior visual pathway (observed
as RNFL and retinal neuronal layer thinning quantified using
OCT technology) [20, 21]. Saidha et al. [20] demonstrated the
presence of retinal ganglion layer thinning in patients with
relapsing-remitting and progressive MS and its correlation
with high and low contrast visual acuity scores. Similarly,
Burkholder et al. showed a significant correlation between
altered visual function scores and reducedmacular volume in
these patients [21]. More importantly, retinal measures inMS
patients evaluated using OCT technology seem to correlate
directly with brain-substructure volumes and grey and white
matter volumes and inversely with FLAIR-lesion volume, as
objectified byMRI, thus reflecting a possible correlation with
general central nervous system pathology in MS [22].
This axonal loss in MS, as observed by OCT, is associated
with physical and cognitive disability as measured by the
Expanded Disability Status Scale (EDSS) [23–25] and has
demonstrated its utility as a biomarker of disease progression
[5, 22, 26, 27]. Recently, pRNFL atrophy was associated with
worsening disability and lower quality of life [28]. Garcia-
Martin et al. analyzed the structural change in the retina of
MSpatients for a time lapse of 3 years anddemonstrated that a
reduction in the pRNFL thickness in these patients was asso-
ciatedwith lower quality of life (measured using theMSQOL-
54 questionnaire) and greater disability. The MSQOL-54
questionnaire is a multidimensional health-related quality
of life measure that combines both generic and MS-specific
items into a single instrument. This 54-item questionnaire
generates 12 subscales (physical function, role limitations:
physical, role limitations: emotional, pain, emotional well-
being, energy, health perceptions, social function, cognitive
function, health distress, overall quality of life, and sexual
function) alongwith two summary scores (the physical health
composite summary and the mental health composite) and
two additional single-itemmeasures (satisfaction with sexual
function and change in health). In Garcia-Martin’s study the
physical health composite of the MSQOL-54 questionnaire
(composed of different questions about the patient’s percep-
tion of their physical condition to fulfill every day’s tasks) was
especially correlated with pRNFL thickness. Additionally, the
baseline mean and superior pRNFL thicknesses appear to
predict decreases in the quality of life in patients with MS
[28].
RNFL thickness decreases with normal aging [29]. How-
ever, compared to healthy subjects, MS patients present with
a higher reduction and more affected sectors of the pRNFL
thickness (Figures 1 and 2) and this reduction seems to be
even greater in untreated patients [30]. More recently, the
pRNFL thickness was pointed out as a good predictor of
the likelihood of disability worsening in MS patients over
time [9]. Patients who had a pRNFL ≤ 92-93 𝜇m showed a
58% increase in the risk of disability worsening, and patients
in the lower pRNFL thickness tertile displayed increased
risk of disability worsening compared to those in the higher
tertile. Patients with pRNFL ≤ 87/88𝜇m doubled the risk
of disability worsening at any time after the first year and
until the third year of follow-up. This disability worsening
prediction by pRNFL seems to be dependent on the follow-up
time, since this risk almost increased fourfold after the third
year and until the fifth year of follow-up.This increased risk of
disability worsening was present in patients with and without
a previous ON episode, although it was higher in patients
with MSON [9].
Combined RNFL parameters were also demonstrated to
improve the ability of this technology to distinguish between
eyes from MS patients and eyes from healthy subjects, by
calculating a linear discriminant function [6]. Mathematical
analysis showed that a linear discriminant function where
different RNFL parameters (thickness in different sectors)
were combined yielded the highest sensitivity at a high speci-
ficity compared to any single sector of the OCT parameters
[6].
2.2. Retinal Segmentation Analysis: Ganglion Cell LayerThick-
ness as a Biomarker for MS. Histopathologic evaluation of
postmortem MS eyes revealed the loss of inner nuclear layer
neurons and significant ganglion cell and inner plexiform
layer (GCIPL) atrophy [14], even in cases where the number
of axons remained intact [31]. New spectral-domain (SD)
OCT segmentation software allows for the measurement of
the various retinal layers separately, taking in vivo measure-
ments one step closer to histologic observations. Current
studies using this segmentation analysis software demon-
strated a reduction of the inner retinal layers, including the
GCIPL, suggesting ganglion cell loss [20, 32–34]. Moreover,














Figure 1: Optic nerve head (a) and retinal nerve fiber layer analysis (b) as obtained with swept-source optical coherence tomography in a
43-year-old patient with multiple sclerosis who suffered a previous episode of optic neuritis 5 years ago. The pixel map and the clock sector













Figure 2: Mean peripapillary retinal nerve fiber layer (pRNFL) thickness of 100 multiple sclerosis (MS) patients compared with 97
healthy controls, as measured with optical coherence tomography. The peripapillary area is divided into 6 different sectors (superonasal,
superotemporal, nasal, inferonasal, inferotemporal, and temporal) and average thickness. All measurements except nasal thickness were
found to be significantly reduced in MS patients compared to controls (Garcia-Martin et al., data not published).
this GCIPL reduction is also correlated with reduced visual
function, functional disability as measured by the EDSS,
and vision-specific quality of life in MS patients [32, 34].
Does this all mean that the GCIPL could be a more precise
biomarker than the RNFL? In a recent study comparing both
GCIPL and pRNFL thickness, average GCIPL was altered
more frequently than average pRNFL, and GCIPL thickness
was demonstrated to have better sensitivity than temporal
pRNFL thickness for detecting retinal thickness changes in
patients with MS [35, 36]. Additionally, logistic regression
analysis demonstrated that GCIPL thickness is a potential
predictor of axonal damage in patients with MS, whereas the
thickness of all other retinal layers (including the RNFL) was
not predictive of axonal atrophy [34]. Thus, GCIPL thickness
has rapidly emerged as a useful structural biomarker in
MS, even better than RNFL thickness, probably because
the neuronal cell bodies suffer an earlier affectation than
the retinal axons in MS. Some authors, ophthalmologists
and neurologists, have suggested that OCT measurements
may be more accurate than MRI parameters to determine
progression in MS patients [9, 34].
3. Parkinson Disease
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder in the developed world (after
Alzheimer’s disease) and is characterized by motor symp-
toms, such as resting tremor, bradykinesia, and rigidity.
However, a large variety of nonmotor symptoms are also
present in this disease: mood [37, 38], cognitive dysfunction
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[39], autonomic failure [40], and sleep disorders [41] are
highly common in PD patients.
Vision is one of the nonmotor systems altered in PD,
reporting decreased visual acuity, contrast sensitivity, or
colour vision reduction [42–48].
Postmortem neurochemical analysis of eyes of deceased
patients diagnosed with PD has shown decreased retinal
dopamine concentration [49, 50]. Dopamine in the human
retina is released by a set of amacrine cells located in the prox-
imal inner nuclear layer of the retina. These dopaminergic
cells communicate with other types of amacrine cells modu-
lating the interconnections between bipolar and retinal gan-
glion cells and also send long processes to other retinal layers,
thus playing a pivotal role in channelling visual information
“vertically” through the retina [51]. Dopamine in the mam-
malian retinamodulates colour vision and contrast sensitivity
through dopaminergic receptors (D1 and D2), which are dif-
ferentially located in the retinal layers. A complete lack of this
dopaminergic receptor activation leads to signal dispersion
and alterations in colour vision and contrast sensitivity.
3.1. RNFLThickness as a Possible Biomarker for PD Diagnosis.
Retinal changes in PDwere first reported in 2004 by Inzelberg
et al. [52], who demonstrated RNFL thickness reduction in
the peripapillary area in a small group of 10 PD patients.
In the following years, research on this topic increased
dramatically and Inzelberg’s results were confirmed by other
studies using time-domainOCT [53–55].Mean and temporal
pRNFL thickness seem to be most affected based on these
studies. Later, studies using SD-OCT also demonstrated
significant reduction of the inferior pRNFL thickness (along
with mean and temporal reduction) [56]. Retinal thickness
in the macular area and total macular volume are also sig-
nificantly reduced in PD [53, 56–58]; however not all studies
demonstrating macular thinning in these patients could find
similar differences in the pRNFL measurements [59–61].
3.2. Macular Thickness as a Biomarker for Disease Progression
and Severity. Macular measurements appear to be an impor-
tant feature in PD. Based on Spectralis OCTmeasurements, a
linear discriminant function was designed by Garcia-Martin
et al. to combine parameters improving the diagnostic ability
of OCT: a calculated retinal linear discriminant function
including different macular thickness measurements yielded
the highest sensitivity at a high specificity compared to any
single parameter determined using OCT or any other linear
discriminant function calculated from pRNFL measure-
ments, suggesting that macular measurements in PD could
be a stronger marker for PD diagnosis [8]. A remodelling of
the foveal pit caused by PD has also been suggested [62].
There is an association between macular thinning and
disease progression and severity in PD. Altintas¸ et al. demon-
strated a relation between PD severity and alterations in
foveal thickness using time-domain OCT [54]. An associ-
ation between disease severity as measured by the Hoehn
Yahr scale and macular thickness was also found using SD-
OCT [57, 63]. Disease severity based on the commonly used
Unified Parkinson’s Disease Rating Scale III (UPDRS III) and
quality of life (based on the Schwab England scale) is also cor-
related with macular measurements, especially temporal and
inferior sectors [57, 63]. Contrary to macular measurements,
correlations between disease severity/duration and pRNFL
thickness have proved to be scarce or nonexistent [55, 57].
3.3. Retinal Segmentation Analysis: Ganglion Cell LayerThick-
ness as a Biomarker for PD. As research on PD moved
forward, SD-OCT segmentation analysis was also applied to
the evaluation of the retina of PD patients (Figures 3 and 4).
In a recent study by Blennow et al., the inner retinal layer
(IRL, defined as the internal limitingmembrane + nerve fiber
layer + ganglion cell layer + inner plexiform layer down to the
inner nuclear layer interface) was found to be reduced in the
perifoveal area of PD patients compared to healthy subjects
[64]. Furthermore, when single retinal layers were measured,
reductions in the macular RNFL, the ganglion cell layer
(GCL), the inner plexiform layer (IPL), the inner nuclear
layer, and the outer plexiform layer were demonstrated [63].
However, only the GCL predicts axonal damage in PD
patients [63]. Segmentation analysis also revealed that the
inner retinal layers of the macular area (RNFL, GCL, and
IPL) are more affected with disease duration and that GCL
thickness is inversely correlated with disease duration and
disease severity [63]. Therefore and based on these recent
segmentation studies the inner retinal layers of the macular
area should be pointed at as the strongest biomarkers for PD
diagnosis and progression.
4. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most frequent cause of
dementia worldwide [64]. Although it is most commonly
associated with memory deficits and cognitive impairment,
patients with AD also exhibit alterations in visual processing
[65–67]. Colour vision and contrast sensitivity alterations are
frequently present and have been suggested as predictors for
cognitive dysfunction [66].
4.1. RNFL Measurements in Alzheimer’s Disease. It has been
postulated that defects in the pRNFL may be the earliest sign
of AD, even before damage to the hippocampus occurs [68].
A reduction in the pRNFL thickness was observed in AD
patients [69–71], especially in mean and inferior sectors [72,
73]. However, one study did not find significant differences
in the pRNFL thickness between AD patients and healthy
controls [74].
4.2. MacularMeasurements as a Biomarker of Disease Severity
in AD. Macular thickness and macular volume are impor-
tantly affected in patients with AD [72–75] and a correlation
between macular volume and cognitive impairment was
suggested [71]. Although foveal thickness is not considered
a useful parameter to detect atrophy in AD [76], the inner
and outer ETDRS sectors of the macula seem to be highly
affected in these patients [73]. However, it is the combination
of the pRNFL parameters (in a calculated linear discrim-
inant function) that seems to show the highest diagnostic







Figure 3: Example of segmentation analysis of the different retinal layers, in a cross-sectional linear scan of the macular area (a), obtained
with Spectralis optical coherence tomography, in a healthy control (b) and a patient diagnosed with Parkinson disease (c). The marked lines
are automatically provided by the segmentation software and represent the different layers of the retina. Corresponding acronyms are also
provided by the segmentation software: ILM: inner limiting membrane; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner












































































Figure 4: Example of segmentation analysis of the macular ganglion cell layer, obtained with Spectralis optical coherence tomography, in a
healthy control (a) and a patient diagnosed with Parkinson disease (b). The segmentation report shows the ganglion cell layer thickness (in
microns) and total volume (in mm3) of the ETDRS macular area. In this patient (b), the central and inner macular areas present thinning of
the ganglion cell layer, compared with the healthy control (a).
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accuracy in AD, compared to combined macular thickness
measurements or single thickness sectors [73]. More studies
on discriminant linear function including macular volume
are needed to corroborate whether macular measurements
are a good biomarker for AD diagnosis.
4.3. Retinal Segmentation Analysis: Ganglion Cell LayerThick-
ness as a Biomarker for Diagnosis and Disease Severity in AD.
Taking a step further into research on retinal biomarkers for
AD, segmentation analysis of the retinal layers was recently
introduced in AD studies. A previous study on postmortem
AD patients did not find any evidence for ganglion cell
loss compared to controls [77]. However, the sample size in
Curcio study was extremely small. Other histopathological
studies have suggested that disease pathology in the pre-
cortical visual system (i.e., the retina and optic nerve) is a
possiblemechanismunderlying visual impairments observed
in AD patients andmay be related to ganglion cell alterations.
Different sets of ganglion cells (parvocellular, magnocellular,
and koniocellular ganglion cells) located in the retinal GCL
result in three different pathways which identify colour and
spatial contrast at different frequencies [78–80]. Previous
studies (histologic, electroretinogram, and imaging studies)
of these pathways suggest that the general loss of magno-
cellular and parvocellular cells of the retina is likely to be
an important contributorymechanism for visual impairment
in AD [81]. Dendritic atrophy and loss of retinal ganglion
cells have also been observed in the retina of a mouse
model of AD, where the accumulation of beta-amyloid in the
inner retinal layers was observed [82]. These beta-amyloid
deposits may be responsible for the depletion of parvo- and
magnocellular cells in the retina and may be linked to visual
function impairment. Moreover, results of this study suggest
that dendritic atrophy of the retinal ganglion cells precedes
ganglion cell loss. Since dendrites of the ganglion cells are
confined to the IPL, this layer could also play a major role
as a biomarker for neuronal damage in AD [82].
According to previous studies, recent animal research
showed inner retinal dysfunction in a mouse model for AD
[83]. Retinal segmentation analysis with OCT in this animal
model demonstrated RNFL thinning, but no associated
changes were observed in the ganglion cell complex [83].
Contrary to the animal model, patients with AD present a
reduction of the RNFL, GCL, and IPL observable with the
OCT segmentation software [84, 85], and these inner layers
are also more affected in those patients with longer course
of the disease [85]. Importantly, when compared to RNFL
thickness, GCIPL presents higher sensitivity to discriminate
AD patients from controls [84]. Moreover, the GCL and
IPL are predictors of axonal damage in these patients and
GCL is associated with disease duration and severity [85].
Based on these findings, it is possible that the combination
of measurements of the retinal inner layers might be the
ultimate biomarker for diagnosis and progression in AD.
5. Future Directions
The unique accessibility of the retina and optic nerve to in
vivo measurements and the structure-function correlations
provided by the afferent visual system in multiple sclerosis,
Parkinson’s disease, and Alzheimer’s disease make the anal-
ysis of the retinal structures a useful model system to test
new therapies. However, there are currently very few studies
focusing on the evaluation of treatment effectiveness through
OCT analysis. Further research remains to be done in a
number of areas, including practical aspects of implementing
clinical outcome measures in multicentre studies, further
validation of other biomarkers (fluid-based biomarkers and
other imaging techniques) development, and the evaluation
of new different therapies effectiveness. Longitudinal studies
are also key in the development of biomarkers for disease
progression. Most studies evaluated in this review include
only cross-sectional data, which is an important limitation
for the analysis of imaging biomarkers, especially for disease
progression and treatment effectiveness. We believe more
longitudinal studies should be carried out, especially in PD
and AD patients, since progressive changes in these two
diseases have not yet been investigated.
6. Conclusions
In the past decade, OCT technology has proved its utility
in the diagnosis and progression of neurodegenerative dis-
eases. Numerous clinical studies have demonstrated that the
RNFL and macular thickness are useful markers for disease
progression and prognosis in MS, PD, and AD. New OCT
segmentation software has also allowed better understanding
of the physiopathology of axonal degeneration in these
neurological diseases through the objective observation of
the different retinal layers. Recent research using the latest
imaging technology in ophthalmology has demonstrated that
an early damage of the anterior visual pathway occurs in MS,
PD, and AD and that the ganglion cell layer is the ultimate
biomarker for disease diagnosis, severity, and progression.
Thus, OCT technology should be used as a common and very
useful clinical complement in the diagnosis and control of
neurodegenerative disorders.
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